These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26563902)

  • 1. Thyroid remnant ablation success and disease outcome in stage III or IV differentiated thyroid carcinoma: recombinant human thyrotropin versus thyroid hormone withdrawal.
    Vallejo Casas JA; Mena Bares LM; Gálvez Moreno MA; Moreno Ortega E; Marlowe RJ; Maza Muret FR; Albalá González MD
    Q J Nucl Med Mol Imaging; 2016 Jun; 60(2):163-71. PubMed ID: 26563902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
    Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
    J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
    Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
    Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioiodine thyroid remnant ablation after recombinant human thyrotropin or thyroid hormone withdrawal in patients with high-risk differentiated thyroid cancer.
    Pitoia F; Marlowe RJ; Abelleira E; Faure EN; Bueno F; Schwarzstein D; Lutfi RJ; Niepomniszcze H
    J Thyroid Res; 2012; 2012():481568. PubMed ID: 23304637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: comparison of thyroid-stimulating hormone stimulation methods.
    Vallejo Casas JA; Mena Bares LM; Gálvez MA; Marlowe RJ; Latre Romero JM; Martínez-Paredes M
    Nucl Med Commun; 2011 Sep; 32(9):840-6. PubMed ID: 21691237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
    Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
    Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human thyrotropin-stimulated thyroglobulin level at the time of radioactive iodine ablation is an independent prognostic marker of differentiated thyroid carcinoma in the setting of prophylactic central neck dissection.
    Moon JH; Choi JY; Jeong WJ; Ahn SH; Lee WW; Kim KM; Choi SH; Lim S; Park YJ; Yi KH; Park do J; Jang HC
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):459-65. PubMed ID: 26833982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
    Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
    Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study.
    van der Horst-Schrivers AN; Sluiter WJ; Muller Kobold AC; Wolffenbuttel BH; Plukker JT; Bisschop PH; de Klerk JM; Al Younis I; Lips P; Smit JW; Brouwers AH; Links TP
    PLoS One; 2015; 10(3):e0120184. PubMed ID: 25793762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients.
    Rosario PW; Xavier AC; Calsolari MR
    Thyroid; 2010 Nov; 20(11):1247-52. PubMed ID: 20950256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.
    Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J
    Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
    Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
    Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
    Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
    Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
    Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis.
    Fu H; Ma C; Tang L; Wu F; Liu B; Wang H
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):121-8. PubMed ID: 24844252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.